Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Alexza, Ferrer Launch Adasuve Agitation Drug in Romania

By R&D Editors | March 14, 2014

Alexza Pharmaceuticals Inc. and Ferrer announced that Adasuve inhalation powder, pre-dispensed (loxapine), is now available in Romania. Ferrer is Alexza’s commercial partner for Adasuve in the European Union (EU), Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a distribution agreement with Galenica SA.
 
“With the launch of Adasuve in Romania, Ferrer is continuing to execute on its planned commercial launch. We are very pleased with Ferrer’s progress in making Adasuve available in the EU,” said Thomas B. King, President and CEO of Alexza. “Manufacturing finished product for our commercial partners is one of Alexza’s key priorities and we continue to support the global introduction of Adasuve.”
 
Alexza received marketing authorization for Adasuve from the European Commission in February 2013. Adasuve is the first inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder authorized for marketing in the EU. The marketing authorization for Adasuve requires that patients receive regular treatment immediately after administration of the product to control acute agitation symptoms. It also requires that Adasuve be administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should also be available for treatment of possible severe respiratory side effects, such as bronchospasm.
 
Alexza and Ferrer estimate that as many as 8 million adults in the EU alone suffer from schizophrenia or bipolar disorder. Agitation is a common symptom for these patients, characterized by feelings of distress, anxiety and loss of control. 
 
Alexza Pharmaceuticals Inc. and Grupo Ferrer Internacional SA are parties to the collaboration agreement for Adasuve pursuant to which Alexza, as the exclusive supplier of Adasuve, is responsible for all aspects of manufacture of the product in its Mountain View, Calif., facility. Ferrer is expected to launch Adasuve in additional EU countries in 2014 and 2015.
 
Date: March 13, 2014
Source: Alexza
 

Related Articles Read More >

PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
R&D 100 winner of the day: Portable EnGineered Analytic Sensor with aUtomated Sampling (PEGASUS)
UCLA bioengineers develop new class of human-powered bioelectronics
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars